TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Hemicraniectomy for Malignant Middle Cerebral Artery Infarction (HeMMI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between 18 to 65 years old who presented with clinical signs of infarction of the MCA territory and who arrived at the hospital within 72 hours of symptom onset. Other inclusion criteria included a Glasgow coma score (GCS) of 6 to14 in patients with right MCA infarction or GCS 5 to 9 in patients with left MCA infarction (adjusted to account for effect on speech deficit on GCS scores), or GCS of 15 on arrival but subsequently deteriorated neurologically as defined by a score of ≥1 on the level of consciousness item of the National Institutes of Health Stroke Scale (NIHSS);computed tomography (CT) scan of the head showing ischemic changes corresponding to more than 50% of the MCA territory with or without involvement of other vascular territories;and written informed consent from the patient or a legal representative.~Exclusion Criteria:~* Patients with previous disabling neurological disease, an estimated premorbid modified Rankin Scale (mRS) score \>2; terminal illness; presence of serious medical comorbidities like end-stage renal failure and cardiac disease with severe hemodynamic compromise; infarction due to surgical complications or vasospasm; primary intracranial hemorrhage; coagulopathies; and high risk for surgery upon assessment by the medical team.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Medical Treatment Arm (Type: OTHER): Received standardized medical therapy in an intensive care unit (ICU), which included elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L. Hyperglycemia, hyperthermia and hypotension were avoided or corrected when present.
- Surgery with Medical Treatment Arm (Type: OTHER): Aside from receiving standardized medical therapy, decompressive hemicraniectomy was performed by removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank. Cranioplasty was performed during a separate admission on an elective basis not earlier than 6 months from the initial surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Surveillance For New Lung Primaries

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Asymptomatic~Exclusion Criteria:~* 20 pack year history

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Radiographic and Patient Outcomes Following Lumbar Spine Fusion Using Demineralized Bone Matrix (DBM) Mixed With Autograft

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is indicated for primary lumbar fusion of 1 or 2 segments, L2 to S1~* Patient is willing to be blindly randomized to treatment or control and remain blinded for 2 years of follow-up~* Patient is at least twenty-one (21) years of age~* Patient is expected to survive at least 2 years beyond surgery~* Patient is willing to participate by complying with pre- and postoperative visit requirements, including: completion of questionnaires, functional performance tests, and radiographs/CT scan~* Patient is willing and able to review and sign a study Informed Consent form~Exclusion Criteria:~* Patient has a mental or physical condition that would invalidate evaluation results~* Patient is pregnant~* Patient is a prisoner~* Patient has a systemic infection or infection at the proposed surgical site~* Patient has osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated~* Patient has a disease of bone metabolism~* Patient is undergoing chemotherapy or radiation treatment~* Patient is currently involved in a study of another product for a similar purpose~* Patient requires post-op management with nonsteroidal anti-inflammatory drugs (NSAIDs)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- O (Type: ACTIVE_COMPARATOR): This treatment arm includes autograft harvested from local bone and / or the iliac crest, supplemented with a demineralized bone matrix (DBM) autograft extender, Optecure.
- A (Type: ACTIVE_COMPARATOR): This treatment arm includes autograft harvested from local bone and / or the iliac crest.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nesiritide Use Following Cardiac Surgery in Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 48 hours after cardiac surgery requiring cardiopulmonary bypass~* \< 1 year of age~* Receiving chlorothiazide and furosemide for \> 12 hours~* Urine output \< 4 cc/kg/hour, or fluid intake \> output for 2 consecutive days~* Receiving mechanical ventilation~* Presence of body wall edema on CXR, defined as a radiologic index of \> 2~* Plan for \> 24 hrs further diuresis before chest closure or extubation~Exclusion Criteria:~* Age \> 365 days at the time of enrollment~* Corrected estimated gestational age \< 35 weeks at the time of enrollment~* Serum creatinine \> 2.0 mg/dL at the time of enrollment~* Significant hemodynamic instability at the time of enrollment~* Lack of dedicated intravenous access for nesiritide infusion~* Lack of arterial line for continuous blood pressure monitoring~* Lack of a Foley catheter for continuous urine collection~* Enrollment in another research study such that the outcomes of either study may be confounded by participation in this study, or such that the amount of blood drawn for research purposes becomes excessive.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Year
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): In this crossover pilot study, patients are randomly assigned to receive either nesiritide or placebo infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.
- Nesiritide (Type: EXPERIMENTAL): In this crossover pilot study, patients are randomly assigned to receive either nesiritide or placebo infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Apixaban For Thromboprophylaxis In Patients With Acute Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (≥18 years old) with acute spinal cord injury (SCI) presenting to the hospital within 1 week of SCI and is at least 36 h after the injury~* Traumatic SCI~* SCI with or without other injuries~Exclusion Criteria:~* Already on therapeutic oral anticoagulation prior to enrollment~* Active bleeding, intracranial or perispinal hematoma, or acquired or congenital bleeding disorder~* Pregnancy or breast feeding~* Severe renal failure (creatinine clearance ≤30 ml/min)~* Liver cirrhosis~* Severe thrombocytopenia (platelets \<50)~* Attending physician believes that the patient is not suitable for the study (for example, psychiatric disorder; history of non-compliance)~* Geographic inaccessibility: planned transfer to other site where follow-up not possible~* Failure to obtain written consent~* Previous hypersensitivity reaction to study drugs~* Patients with expected short hospital admission (≤7 days) due to minor injury

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apixaban (Type: EXPERIMENTAL): Apixaban 2.5 mg orally twice daily
- Low Molecular Weight Heparin (Type: ACTIVE_COMPARATOR): Either enoxaparin 40 mg or dalteparin 5000 units subcutaneously once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of a Single-Use, Point-of-Care Molecular Diagnostic Device for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) Utilizing Vaginal Swabs

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Willing and able to give voluntary written informed consent (or the parent/legal guardian will provide parental permission) before any study-related procedure is performed.~2. Female at birth. (Pregnant and breastfeeding women are eligible)~3. Age \> / = 14 years at the time of enrollment.~4. Able to read and understand the procedural information provided for the study.~5. Able and willing to follow all study procedures, including performing self-collection of one vaginal swab and permitting a licensed health care provider to collect three additional vaginal swabs.~Exclusion Criteria:~1. Have a medical condition, serious intercurrent illness, or other circumstance that, in the Investigator's judgment, could jeopardize the subject's safety, or could interfere with study procedures.~2. Enrollment in this study previously.

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Click Device (Type: EXPERIMENTAL): One self collected vaginal swab for Click Device testing. Three health care provider collected vaginal swabs for comparator testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid/Chondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis/Bladder Pain Syndrome.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. must have experienced bladder pain, urinary urgency and urinary frequency, for at least 6 months prior to entry into the study~2. Pain VAS ≥4~3. O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q) symptom and problem ≥ 12( and pain ≥2, and nocturia ≥ 2)~4. PUF score ≥ 13~5. cystoscopic record within 2 years~6. Hunner ulcer lesion in cystoscopic finding~Exclusion Criteria:~1. Scheduled for or use of intravesical therapy (eg, bladder distention,transurethral resection of bladder ulcer, instillation) during or within 6months prior to the study and use of pentosan polysulfate sodium within 1 months prior to the study~2. Patients who are pregnancy or, childbearing age without no contraception~3. Patients with voided volume \<40 or, \> 400ml~4. Patients with microscopic hematuria, (≥1+ in dipstick), If not excluded that no evidence of neoplastic tumor examination~5. Patients with urine culture showing evidence of urinary tract infection 1month prior to the study~6. Accompanied medical problem below~   * Tuberculosis in urinary system~  * Bladder cancer, urethral cancer, prostate cancer~  * Recurrent cystitis~  * anatomical disorder~7. Patients had prior surgery (eq, bladder augmentation, cystectomy~8. Patients with neurologic disorder~9. Patients with indwelling catheter or intermittent self-catheterization~10. Patients with psychologic problem

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Additional instillation of hyaluronic acid/chondroitin sulfate (Type: EXPERIMENTAL): Transurethral resection of bladder ulcer + instillation of hyaluronic acid/chondroitin sulfate
- Transurethral resection of bladder ulcer (Type: ACTIVE_COMPARATOR): Transurethral resection of bladder ulcer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject is is greater than or equal to 18 years of age.~* The subjects has highly suspected or established carotid artery disease.~* The subject has undergone or been referred for either unilateral or bilateral intra-arterial X-ray carotid angiography for the determination of subject management (within 30 days before or after the U/S procedure).~* The subject has non-diagnostic U/S of the carotids as defined by institutional standards.~Exclusion Criteria:~* The subject presents any clinically active, serious, life-threatening disease, with a life expectancy of less than 1 month or where study participation may compromise the management of the subject or other reason that in the judgment of the investigator makes the subject unsuitable for participation in the study.~* The subject has a history of acute occlusion requiring medical intervention of any artery (including aorta) within 6 months of consent.~* The subject has a known or suspected hypersensitivity to any of the components of Optison, blood, blood products, or albumin.~* The subject has right to left, bi-directional or transient right to left cardiac shunts.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm Number 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Hypoxia as a Selective Pressure for TP53 Mutations

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. ≥18 years of age on the day of signing the informed consent.~2. Histologically confirmed endometroid or serous endometrial cancer.~3. Scheduled to have hysterectomy at the cancer centre~4. Identifiable tumour mass on staging MRI.~5. Voluntarily agreed to participate by giving written informed consent.~Exclusion Criteria:~1. Life expectancy of \< 6 months.~2. Ferromagnetic implants, contraindicating MRI~3. Claustrophobia so unable to tolerate MRI~4. Unable to lie flat~5. Ascites sufficient to prevent patient being fitted in the scanner bore~6. Histology unlikely to show variation in TP53 status, or heavily calcified disease.~7. Radiotherapy to the abdomen or pelvis within 6 months of the screening visit.~8. Unresolved bowel obstruction.~9. Currently participating or has participated in a study with an investigational compound or device within 30 days of the start of treatment.~10. History or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with patient's participation for the full duration of the study, or is not in the best interest of the patient to participate.~11. Unlikely to comply with the requirements of the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Endometriod (Type: None): Type I (endometrioid and mucinous carcinomas) - Magnetic Resonance Imaging (MRI) with 100% Oxygen.
- Serous (Type: None): Type II (serous and clear cell carcinomas) - Magnetic Resonance Imaging (MRI) with 100% Oxygen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does Caffeine Reduce Postoperative Bowel Paralysis After Elective Colectomy?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for elective laparoscopic colectomy (right or left hemicolectomy, segmental resection, extended hemicolectomy, sigmoid resection, upper rectum (anastomosis higher than 7 cm ab ano))~* There will be no upper age limit. If elderly patients are considered fit for surgery, they will be included in the study.~* Informed consent~* Application of epidural analgesia~Exclusion Criteria:~* Participation in another concurrent interventional trial~* Need for a stoma (colostomy or ileostomy) or reversal of a stoma, if the patient had a complete bowel obstruction~* Known hypersensitivity or allergy to caffeine/coffee~* Expected lack of compliance~* American Society of Anesthesiologists (ASA) Physical Status Score of IV or V~* Impaired mental state or language problems~* Alcoholism or drug abuse~* Previous extensive abdominal surgery~* Inflammatory bowel disease~* Clinically significant cardiac arrhythmia~* Cardiac insufficiency~* Pregnancy, lactation, or childbearing potential without using adequate contraception~* Intake of opioid analgesics, or steroids \>5mg/d for ≥7 days before surgery~* Under anti-depressive medication~* Liver cirrhosis or compromised liver function (MELD score \>15)~* Emergency procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Caffeine (100 mg) (Type: EXPERIMENTAL): Verum 1 with 100 mg caffeine
- Caffeine (200 mg) (Type: EXPERIMENTAL): Verum 2 with 200 mg caffeine
- corn starch (250 mg approx.) (Type: PLACEBO_COMPARATOR): approx. 250 mg corn starch as placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Recover L-PRP in Lateral Epicondylitis (REGP-11-00)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Signed an independent ethics committee (IEC)-approved informed consent form (ICF).~2. Male or female of ≥ 18 years of age~3. Confirmed diagnosis of unilateral chronic LE~4. Duration of chronic LE symptoms ≥ 3 months~5. Failed at least one previous LE treatment (e.g. wait and see, physiotherapy, analgesics, NSAIDs, anti-inflammatory steroid injection and bracing, etc.).~   Exclusion Criteria:~6. No active systemic inflammatory condition (e.g., rheumatoid arthritis)~7. No active leukemia or metastatic malignant cells~8. No current chemotherapy treatments~9. No pregnancy~10. No lactation~11. No infected tendons, skin infection or skin disease in the area of the injection site.~12. Participating in another drug or device study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Quetiapine for Pediatric Delirium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Any patient in the PICU aged 1 year to 21 years old who is diagnosed with delirium~Exclusion Criteria:~* Age \<1~* Richmond Agitation Sedation Scale (RASS) score of -4 or -5 (deeply sedated or unarousable).~* current treatment for alcohol withdrawal~* hepatic encephalopathy~* pregnancy~* diagnosis of major depressive disorder or bipolar disorder~* diagnosis of movement disorder~* diagnosis of diabetic ketoacidosis~* baseline QTc \>500 milliseconds~* non-English speaking subjects and/or parent/guardian

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- Quetiapine (Type: EXPERIMENTAL): A randomized group will receive quetiapine as treatment for delirium.
- Placebo (Type: PLACEBO_COMPARATOR): A randomized group will receive placebo, and not quetiapine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues